Key facts
- This page summarizes Angie You's Form 4 filing for Attovia Therapeutics, Inc. (ATTO).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 06 Aug 2026, 17:17.
Angie You - 04 Aug 2026 Form 4 Insider Report for Attovia Therapeutics, Inc. (ATTO)
- Reporting relationship
- Director
- Issuer ticker
- ATTO
- Reported as of
- 04 Aug 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 06 Aug 2026, 17:17:47 UTC
- Prior SEC filing
- 06 Jan 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Steven Chan, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Angie You filed Form 4 for Attovia Therapeutics, Inc. (ATTO) on 06 Aug 2026.
Change
- Previous filing in this sequence was filed on 06 Jan 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001647664
Primary reporting owner
You Angie
- Relationship
- Director
- Address
- C/O ATTOVIA THERAPEUTICS, INC., 1091 INDUSTRIAL ROAD, SUITE 310, SAN CARLOS
- Signature
- /s/ Steven Chan, Attorney-in-Fact
- Signature date
- 06 Aug 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ATTO
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +27,000
- Change %
- Price
- $0.000000*
- Shares after
- 27,000
- Date
- 04 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 27,000
- Exercise price
- $17.00
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The options shall fully vest on the earlier of (i) August 4, 2027 and (ii) the next annual meeting of the Company's stockholders, subject to continued service to the Issuer through such date.